{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:40:28Z","timestamp":1793317228322,"version":"4.5.0"},"reference-count":275,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40264-024-01506-5","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T06:39:28Z","timestamp":1735022368000},"page":"339-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Drug-Induced Cognitive Impairment"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-554X","authenticated-orcid":false,"given":"Arne","family":"Reimers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0756-7478","authenticated-orcid":false,"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-1470","authenticated-orcid":false,"given":"Hanna","family":"Ljung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"1","key":"1506_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0733-8619(05)70371-6","volume":"16","author":"KJ Meador","year":"1998","unstructured":"Meador KJ. Cognitive side effects of medications. Neurol Clin North Am. 1998;16(1):141\u201355.","journal-title":"Neurol Clin North Am."},{"issue":"12","key":"1506_CR2","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1093\/ckj\/sfad239","volume":"16","author":"G Hafez","year":"2023","unstructured":"Hafez G, Malyszko J, Golenia A, Klimkowicz-Mrowiec A, Ferreira AC, Arici M, et al. Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients. Clin Kidney J. 2023;16(12):2378\u201392. https:\/\/doi.org\/10.1093\/ckj\/sfad239.","journal-title":"Clin Kidney J"},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-med-042220-013015","volume":"73","author":"NT Prendergast","year":"2022","unstructured":"Prendergast NT, Tiberio PJ, Girard TD. Treatment of delirium during critical illness. Annu Rev Med. 2022;73:407\u201321. https:\/\/doi.org\/10.1146\/annurev-med-042220-013015.","journal-title":"Annu Rev Med"},{"issue":"3","key":"1506_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1082-7579(97)00004-6","volume":"2","author":"SC Stoner","year":"1997","unstructured":"Stoner SC. Drug-induced cognitive dysfunction. Med Update Psychiatrists. 1997;2(3):81\u20135. https:\/\/doi.org\/10.1016\/S1082-7579(97)00004-6.","journal-title":"Med Update Psychiatrists."},{"issue":"6","key":"1506_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.7326\/0003-4819-109-6-476","volume":"109","author":"AM Clarfield","year":"1988","unstructured":"Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med. 1988;109(6):476\u201386. https:\/\/doi.org\/10.7326\/0003-4819-109-6-476.","journal-title":"Ann Intern Med"},{"key":"1506_CR6","doi-asserted-by":"publisher","first-page":"770413","DOI":"10.3389\/fmolb.2021.770413","volume":"8","author":"Z Orszaghova","year":"2021","unstructured":"Orszaghova Z, Mego M, Chovanec M. Long-term cognitive dysfunction in cancer survivors. Front Mol Biosci. 2021;8:770413. https:\/\/doi.org\/10.3389\/fmolb.2021.770413.","journal-title":"Front Mol Biosci"},{"key":"1506_CR7","doi-asserted-by":"crossref","unstructured":"First MB, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth edition, text revision ed. Washington: American Psychiatric Association Publishing; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"4","key":"1506_CR8","first-page":"488","volume":"145","author":"EB Larson","year":"1986","unstructured":"Larson EB, Reifler BV, Sumi SM, Canfield CG, Chinn NM. Features of potentially reversible dementia in elderly outpatients. West J Med. 1986;145(4):488\u201392.","journal-title":"West J Med"},{"issue":"8","key":"1506_CR9","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.amjmed.2017.03.012","volume":"130","author":"JS Alpert","year":"2017","unstructured":"Alpert JS. Polypharmacy in elderly patients: the march goes on and on. Am J Med. 2017;130(8):875\u20136. https:\/\/doi.org\/10.1016\/j.amjmed.2017.03.012.","journal-title":"Am J Med"},{"key":"1506_CR10","unstructured":"National Center for Health Statistics. National Health and Nutrition Examination Survey: Prescription drug use in the past 30 days, by sex, race and Hispanic origin, and age: United States, selected years 1988\u20131994 through 2015\u20132018\u2014Con. Available from: https:\/\/www.cdc.gov\/nchs\/data\/hus\/2019\/039-508.pdf. Accessed Dec 3, 2024"},{"issue":"2","key":"1506_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7326\/0003-4819-107-2-169","volume":"107","author":"EB Larson","year":"1987","unstructured":"Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107(2):169\u201373. https:\/\/doi.org\/10.7326\/0003-4819-107-2-169.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1506_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185\u201396. https:\/\/doi.org\/10.1080\/14740338.2018.1546841.","journal-title":"Expert Opin Drug Saf"},{"key":"1506_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"issue":"1","key":"1506_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12877-022-03279-x","volume":"22","author":"M Delara","year":"2022","unstructured":"Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Prevalence and factors associated with polypharmacy: a systematic review and Meta-analysis. BMC Geriatr. 2022;22(1):601. https:\/\/doi.org\/10.1186\/s12877-022-03279-x.","journal-title":"BMC Geriatr"},{"issue":"6","key":"1506_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/jgs.13517","volume":"63","author":"L Dautzenberg","year":"2015","unstructured":"Dautzenberg L, Jessurum N, Dautzenberg PL, Keijsers CJ. Reversible methotrexate-induced dementia: a case report. J Am Geriatr Soc. 2015;63(6):1273\u20134. https:\/\/doi.org\/10.1111\/jgs.13517.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"1506_CR16","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/archneur.1988.00520270138035","volume":"45","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Como P. Drug-induced alzheimerism. Arch Neurol. 1988;45(3):356\u20137. https:\/\/doi.org\/10.1001\/archneur.1988.00520270138035.","journal-title":"Arch Neurol"},{"issue":"4","key":"1506_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1532-5415.2010.02795.x","volume":"58","author":"MJ Sleegers","year":"2010","unstructured":"Sleegers MJ, Beutler JJ, Hardon WJ, Berden JH, Verhave JC, Conemans JM, et al. Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus. J Am Geriatr Soc. 2010;58(4):799\u2013801. https:\/\/doi.org\/10.1111\/j.1532-5415.2010.02795.x.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"1506_CR18","first-page":"863","volume":"106","author":"U Lindbom","year":"2009","unstructured":"Lindbom U, Taubert B, Fahlqvist MS, Bergens A, Kimland E, Jonsson EW, et al. Reversible dementia-like condition and parkinsonism in an elderly woman. Idiosyncratic adverse effects connected to 11 years of antiepileptic medication. Lakartidningen. 2009;106(12):863\u20135.","journal-title":"Lakartidningen"},{"issue":"4","key":"1506_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1212\/01.WNL.0000151977.18440.C3","volume":"64","author":"O Sacks","year":"2005","unstructured":"Sacks O, Shulman M. Steroid dementia: an overlooked diagnosis? Neurology. 2005;64(4):707\u20139. https:\/\/doi.org\/10.1212\/01.WNL.0000151977.18440.C3.","journal-title":"Neurology"},{"issue":"6","key":"1506_CR20","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/gps.5538","volume":"36","author":"R Howard","year":"2021","unstructured":"Howard R, Schott JM. When dementia is misdiagnosed. Int J Geriatr Psychiatry. 2021;36(6):799\u2013801. https:\/\/doi.org\/10.1002\/gps.5538.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"1506_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.emc.2010.03.005","volume":"28","author":"JH Han","year":"2010","unstructured":"Han JH, Wilson A, Ely EW. Delirium in the older emergency department patient: a quiet epidemic. Emerg Med Clin North Am. 2010;28(3):611\u201331. https:\/\/doi.org\/10.1016\/j.emc.2010.03.005.","journal-title":"Emerg Med Clin North Am"},{"issue":"1","key":"1506_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","volume":"15","author":"AR Moore","year":"1999","unstructured":"Moore AR, O\u2019Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15\u201328. https:\/\/doi.org\/10.2165\/00002512-199915010-00002.","journal-title":"Drugs Aging"},{"issue":"11","key":"1506_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jamda.2014.08.012","volume":"15","author":"C Hein","year":"2014","unstructured":"Hein C, Forgues A, Piau A, Sommet A, Vellas B, Nourhashemi F. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014;15(11):850. https:\/\/doi.org\/10.1016\/j.jamda.2014.08.012. (e11-5).","journal-title":"J Am Med Dir Assoc"},{"issue":"23","key":"1506_CR24","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1001\/jama.2014.13806","volume":"312","author":"KM Langa","year":"2014","unstructured":"Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA. 2014;312(23):2551\u201361. https:\/\/doi.org\/10.1001\/jama.2014.13806.","journal-title":"JAMA"},{"issue":"3","key":"1506_CR25","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-191092","volume":"73","author":"Q Cao","year":"2020","unstructured":"Cao Q, Tan CC, Xu W, Hu H, Cao XP, Dong Q, et al. The prevalence of dementia: a systematic review and meta-analysis. J Alzheimers Dis. 2020;73(3):1157\u201366. https:\/\/doi.org\/10.3233\/JAD-191092.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1506_CR26","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Collaborators GBDDF","year":"2022","unstructured":"Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8.","journal-title":"Lancet Public Health."},{"issue":"12","key":"1506_CR27","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/jnnp-2015-310548","volume":"86","author":"W Xu","year":"2015","unstructured":"Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299\u2013306. https:\/\/doi.org\/10.1136\/jnnp-2015-310548.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1506_CR28","unstructured":"WHO. Dementia. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed Dec 3, 2024"},{"key":"1506_CR29","unstructured":"Alzheimer's Disease International. Risk factors and risk reduction. Available from: https:\/\/www.alzint.org\/about\/risk-factors-risk-reduction\/. Accessed Dec 3, 2024"},{"issue":"10248","key":"1506_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(20)30367-6.","journal-title":"Lancet"},{"key":"1506_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.maturitas.2015.10.008","volume":"83","author":"J Apostolo","year":"2016","unstructured":"Apostolo J, Holland C, O\u2019Connell MD, Feeney J, Tabares-Seisdedos R, Tadros G, et al. Mild cognitive decline A position statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy Ageing (EIPAHA). Maturitas. 2016;83:83\u201393. https:\/\/doi.org\/10.1016\/j.maturitas.2015.10.008.","journal-title":"Maturitas"},{"issue":"4","key":"1506_CR32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/arclin\/acx021","volume":"32","author":"TM Roebuck-Spencer","year":"2017","unstructured":"Roebuck-Spencer TM, Glen T, Puente AE, Denney RL, Ruff RM, Hostetter G, et al. Cognitive screening tests versus comprehensive neuropsychological test batteries: a national academy of neuropsychology education paperdagger. Arch Clin Neuropsychol. 2017;32(4):491\u20138. https:\/\/doi.org\/10.1093\/arclin\/acx021.","journal-title":"Arch Clin Neuropsychol"},{"key":"1506_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jintelligence6010001","author":"D Herreen","year":"2017","unstructured":"Herreen D, Zajac IT. The reliability and validity of a self-report measure of cognitive abilities in older adults: more personality than cognitive function. J Intell. 2017. https:\/\/doi.org\/10.3390\/jintelligence6010001.","journal-title":"J Intell"},{"issue":"1","key":"1506_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jagp.2021.04.004","volume":"30","author":"AM Weinstein","year":"2022","unstructured":"Weinstein AM, Gujral S, Butters MA, Bowie CR, Fischer CE, Flint AJ, et al. Diagnostic precision in the detection of mild cognitive impairment: a comparison of two approaches. Am J Geriatr Psychiatry. 2022;30(1):54\u201364. https:\/\/doi.org\/10.1016\/j.jagp.2021.04.004.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"1506_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47. https:\/\/doi.org\/10.1038\/s41572-021-00280-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1506_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ejpain.2004.10.005","volume":"9","author":"P Sjogren","year":"2005","unstructured":"Sjogren P, Christrup LL, Petersen MA, Hojsted J. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain. 2005;9(4):453\u201362. https:\/\/doi.org\/10.1016\/j.ejpain.2004.10.005.","journal-title":"Eur J Pain"},{"issue":"1\u20132","key":"1506_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jns.2014.05.005","volume":"343","author":"E Chan","year":"2014","unstructured":"Chan E, Khan S, Oliver R, Gill SK, Werring DJ, Cipolotti L. Underestimation of cognitive impairments by the Montreal Cognitive Assessment (MoCA) in an acute stroke unit population. J Neurol Sci. 2014;343(1\u20132):176\u20139. https:\/\/doi.org\/10.1016\/j.jns.2014.05.005.","journal-title":"J Neurol Sci"},{"issue":"2","key":"1506_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-011-0595-4","volume":"105","author":"RA Olson","year":"2011","unstructured":"Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation with community integration and quality of life. J Neurooncol. 2011;105(2):337\u201344. https:\/\/doi.org\/10.1007\/s11060-011-0595-4.","journal-title":"J Neurooncol"},{"issue":"1","key":"1506_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40264-023-01378-1","volume":"47","author":"A Reimers","year":"2024","unstructured":"Reimers A, Ljung H. Cognitive safety is largely ignored in clinical drug trials: a study of registered study protocols. Drug Saf. 2024;47(1):23\u20138. https:\/\/doi.org\/10.1007\/s40264-023-01378-1.","journal-title":"Drug Saf"},{"issue":"4","key":"1506_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077582","volume":"14","author":"A Dugard","year":"2024","unstructured":"Dugard A, Giraudeau B, Dibao-Dina C. Do patients with type 2 diabetes mellitus included in randomised clinical trials differ from general-practice patients? A cross-sectional comparative study. BMJ Open. 2024;14(4): e077582. https:\/\/doi.org\/10.1136\/bmjopen-2023-077582.","journal-title":"BMJ Open"},{"issue":"3 Suppl","key":"1506_CR41","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","volume":"8","author":"TA Jacobson","year":"2014","unstructured":"Jacobson TA. NLA task force on statin safety\u20132014 update. J Clin Lipidol. 2014;8(3 Suppl):S1-4. https:\/\/doi.org\/10.1016\/j.jacl.2014.03.003.","journal-title":"J Clin Lipidol"},{"issue":"Suppl 1","key":"1506_CR42","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.yebeh.2003.11.008","volume":"5","author":"P Ortinski","year":"2004","unstructured":"Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Behav. 2004;5(Suppl 1):S60\u20135. https:\/\/doi.org\/10.1016\/j.yebeh.2003.11.008.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"1506_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eplepsyres.2005.09.023","volume":"68","author":"KJ Meador","year":"2006","unstructured":"Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68(1):63\u20137. https:\/\/doi.org\/10.1016\/j.eplepsyres.2005.09.023.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1506_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3988\/jcn.2008.4.3.99","volume":"4","author":"SP Park","year":"2008","unstructured":"Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. J Clin Neurol. 2008;4(3):99\u2013106. https:\/\/doi.org\/10.3988\/jcn.2008.4.3.99.","journal-title":"J Clin Neurol"},{"issue":"3","key":"1506_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40272-021-00448-0","volume":"23","author":"FMC Besag","year":"2021","unstructured":"Besag FMC, Vasey MJ. Neurocognitive effects of antiseizure medications in children and adolescents with epilepsy. Paediatr Drugs. 2021;23(3):253\u201386. https:\/\/doi.org\/10.1007\/s40272-021-00448-0.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1506_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yebeh.2009.10.019","volume":"17","author":"B Hermann","year":"2010","unstructured":"Hermann B, Meador KJ, Gaillard WD, Cramer JA. Cognition across the lifespan: antiepileptic drugs, epilepsy, or both? Epilepsy Behav. 2010;17(1):1\u20135. https:\/\/doi.org\/10.1016\/j.yebeh.2009.10.019.","journal-title":"Epilepsy Behav"},{"issue":"3","key":"1506_CR47","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yebeh.2012.04.120","volume":"24","author":"SE Marino","year":"2012","unstructured":"Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, et al. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. Epilepsy Behav. 2012;24(3):365\u201372. https:\/\/doi.org\/10.1016\/j.yebeh.2012.04.120.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1506_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14656566.2019.1595584","volume":"20","author":"A Reimers","year":"2019","unstructured":"Reimers A, Ljung H. An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. Expert Opin Pharmacother. 2019;20(8):909\u201315. https:\/\/doi.org\/10.1080\/14656566.2019.1595584.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1506_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1684\/j.1950-6945.2001.tb00398.x","volume":"3","author":"D Battaglia","year":"2001","unstructured":"Battaglia D, Iuvone L, Stefanini MC, Acquafondata C, Lettori D, Chiricozzi F, et al. Reversible aphasic disorder induced by lamotrigine in atypical benign childhood epilepsy. Epileptic Disord. 2001;3(4):217\u201322.","journal-title":"Epileptic Disord"},{"key":"1506_CR50","doi-asserted-by":"publisher","DOI":"10.21926\/obm.neurobiol.2102091","author":"JC Brown","year":"2021","unstructured":"Brown JC, Broadway JL. Lamotrigine-associated progressive dysphasia and cognitive dysfunction. OBM Neurobiol. 2021. https:\/\/doi.org\/10.21926\/obm.neurobiol.2102091.","journal-title":"OBM Neurobiol."},{"key":"1506_CR51","doi-asserted-by":"publisher","first-page":"2064027","DOI":"10.1155\/2018\/2064027","volume":"2018","author":"CC Hansen","year":"2018","unstructured":"Hansen CC, Ljung H, Brodtkorb E, Reimers A. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel. Behav Neurol. 2018;2018:2064027. https:\/\/doi.org\/10.1155\/2018\/2064027.","journal-title":"Behav Neurol"},{"key":"1506_CR52","first-page":"1","volume-title":"Encyclopedia of molecular pharmacology","author":"A Reimers","year":"2020","unstructured":"Reimers A. Antiepileptic drugs. In: Offermanns S, Rosenthal W, editors. Encyclopedia of molecular pharmacology. Cham: Springer International Publishing; 2020. p. 1\u201319."},{"issue":"9","key":"1506_CR53","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","volume":"35","author":"W Loscher","year":"2021","unstructured":"Loscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs. 2021;35(9):935\u201363. https:\/\/doi.org\/10.1007\/s40263-021-00827-8.","journal-title":"CNS Drugs"},{"issue":"1","key":"1506_CR54","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/0883073807307082","volume":"23","author":"E Wirrell","year":"2008","unstructured":"Wirrell E, Sherman EM, Vanmastrigt R, Hamiwka L. Deterioration in cognitive function in children with benign epilepsy of childhood with central temporal spikes treated with sulthiame. J Child Neurol. 2008;23(1):14\u201321. https:\/\/doi.org\/10.1177\/0883073807307082.","journal-title":"J Child Neurol"},{"key":"1506_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107284","volume":"111","author":"P Ramey","year":"2020","unstructured":"Ramey P, Osborn M, Kirshner H, Abou-Khalil B. Misdiagnosis of lamotrigine toxicity as posterior circulation transient ischemic attack or stroke. Epilepsy Behav. 2020;111: 107284. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107284.","journal-title":"Epilepsy Behav"},{"key":"1506_CR56","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.11l01278","author":"NS Westercamp","year":"2012","unstructured":"Westercamp NS, Sharma A. Case report: lamotrigine toxicity leading to depressed mental activity. Prim Care Companion CNS Disord. 2012. https:\/\/doi.org\/10.4088\/PCC.11l01278.","journal-title":"Prim Care Companion CNS Disord."},{"issue":"12","key":"1506_CR57","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s40263-022-00969-3","volume":"36","author":"JA Witt","year":"2022","unstructured":"Witt JA, Widman G, Hansen N, von Wrede R, Elger CE, Helmstaedter C. Evaluation of a rapid topiramate titration scheme for the early detection of cognitive side effects. CNS Drugs. 2022;36(12):1325\u201330. https:\/\/doi.org\/10.1007\/s40263-022-00969-3.","journal-title":"CNS Drugs"},{"key":"1506_CR58","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jad.2017.09.016","volume":"226","author":"K Heser","year":"2018","unstructured":"Heser K, Luck T, Rohr S, Wiese B, Kaduszkiewicz H, Oey A, et al. Potentially inappropriate medication: association between the use of antidepressant drugs and the subsequent risk for dementia. J Affect Disord. 2018;226:28\u201335. https:\/\/doi.org\/10.1016\/j.jad.2017.09.016.","journal-title":"J Affect Disord"},{"issue":"1","key":"1506_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4088\/JCP.14m09580","volume":"77","author":"CW Lee","year":"2016","unstructured":"Lee CW, Lin CL, Sung FC, Liang JA, Kao CH. Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study. J Clin Psychiatry. 2016;77(1):117\u201322. https:\/\/doi.org\/10.4088\/JCP.14m09580. (quiz 22).","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"1506_CR60","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jagp.2019.05.019","volume":"27","author":"A Kodesh","year":"2019","unstructured":"Kodesh A, Sandin S, Reichenberg A, Rotstein A, Pedersen NL, Ericsson M, et al. Exposure to antidepressant medication and the risk of incident dementia. Am J Geriatr Psychiatry. 2019;27(11):1177\u201388. https:\/\/doi.org\/10.1016\/j.jagp.2019.05.019.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"14","key":"1506_CR61","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1080\/14656566.2021.1921736","volume":"22","author":"R Brender","year":"2021","unstructured":"Brender R, Mulsant BH, Blumberger DM. An update on antidepressant pharmacotherapy in late-life depression. Expert Opin Pharmacother. 2021;22(14):1909\u201317. https:\/\/doi.org\/10.1080\/14656566.2021.1921736.","journal-title":"Expert Opin Pharmacother"},{"key":"1506_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.825591","volume":"13","author":"H Qian","year":"2022","unstructured":"Qian H, Shu C, Xiao L, Wang G. Histamine and histamine receptors: Roles in major depressive disorder. Front Psychiatry. 2022;13: 825591. https:\/\/doi.org\/10.3389\/fpsyt.2022.825591.","journal-title":"Front Psychiatry."},{"issue":"2","key":"1506_CR63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbr.2008.12.010","volume":"199","author":"EO Alvarez","year":"2009","unstructured":"Alvarez EO. The role of histamine on cognition. Behav Brain Res. 2009;199(2):183\u20139. https:\/\/doi.org\/10.1016\/j.bbr.2008.12.010.","journal-title":"Behav Brain Res"},{"issue":"7","key":"1506_CR64","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","volume":"71","author":"American Geriatrics Society Beers Criteria Update Expert P","year":"2023","unstructured":"American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2023 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052\u201381. https:\/\/doi.org\/10.1111\/jgs.18372.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"1506_CR65","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0361-9230(01)00780-8","volume":"58","author":"Y Levkovitz","year":"2002","unstructured":"Levkovitz Y, Caftori R, Avital A, Richter-Levin G. The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res Bull. 2002;58(4):345\u201350. https:\/\/doi.org\/10.1016\/s0361-9230(01)00780-8.","journal-title":"Brain Res Bull"},{"issue":"8","key":"1506_CR66","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/gps.2783","volume":"27","author":"ME Culang-Reinlieb","year":"2012","unstructured":"Culang-Reinlieb ME, Sneed JR, Keilp JG, Roose SP. Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline. Int J Geriatr Psychiatry. 2012;27(8):777\u201384. https:\/\/doi.org\/10.1002\/gps.2783.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1506_CR67","doi-asserted-by":"publisher","first-page":"5480391","DOI":"10.1155\/2016\/5480391","volume":"2016","author":"M Sayyah","year":"2016","unstructured":"Sayyah M, Eslami K, AlaiShehni S, Kouti L. Cognitive function before and during treatment with selective serotonin reuptake inhibitors in patients with depression or obsessive-compulsive disorder. Psychiatry J. 2016;2016:5480391. https:\/\/doi.org\/10.1155\/2016\/5480391.","journal-title":"Psychiatry J"},{"issue":"2","key":"1506_CR68","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1176\/appi.focus.20150043","volume":"14","author":"T Chakrabarty","year":"2016","unstructured":"Chakrabarty T, Hadjipavlou G, Lam RW. Cognitive dysfunction in major depressive disorder: assessment, impact, and management. Focus (Am Psychiatr Publ). 2016;14(2):194\u2013206. https:\/\/doi.org\/10.1176\/appi.focus.20150043.","journal-title":"Focus (Am Psychiatr Publ)."},{"issue":"11","key":"1506_CR69","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1037\/bul0000344","volume":"147","author":"TA James","year":"2021","unstructured":"James TA, Weiss-Cowie S, Hopton Z, Verhaeghen P, Dotson VM, Duarte A. Depression and episodic memory across the adult lifespan: a meta-analytic review. Psychol Bull. 2021;147(11):1184\u2013214. https:\/\/doi.org\/10.1037\/bul0000344.","journal-title":"Psychol Bull"},{"key":"1506_CR70","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jad.2014.11.008","volume":"173","author":"D Popovic","year":"2015","unstructured":"Popovic D, Vieta E, Fornaro M, Perugi G. Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants. J Affect Disord. 2015;173:211\u20135. https:\/\/doi.org\/10.1016\/j.jad.2014.11.008.","journal-title":"J Affect Disord"},{"issue":"8","key":"1506_CR71","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hup.725","volume":"20","author":"EJ Wadsworth","year":"2005","unstructured":"Wadsworth EJ, Moss SC, Simpson SA, Smith AP. SSRIs and cognitive performance in a working sample. Hum Psychopharmacol. 2005;20(8):561\u201372. https:\/\/doi.org\/10.1002\/hup.725.","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"1506_CR72","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.euroneuro.2009.11.009","volume":"20","author":"A Serretti","year":"2010","unstructured":"Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D. Antidepressants in healthy subjects: what are the psychotropic\/psychological effects? Eur Neuropsychopharmacol. 2010;20(7):433\u201353. https:\/\/doi.org\/10.1016\/j.euroneuro.2009.11.009.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"5","key":"1506_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011200","volume":"6","author":"KB Leth-Moller","year":"2016","unstructured":"Leth-Moller KB, Hansen AH, Torstensson M, Andersen SE, Odum L, Gislasson G, et al. Antidepressants and the risk of hyponatremia: a Danish register-based population study. BMJ Open. 2016;6(5): e011200. https:\/\/doi.org\/10.1136\/bmjopen-2016-011200.","journal-title":"BMJ Open"},{"issue":"4","key":"1506_CR74","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.maturitas.2013.08.010","volume":"76","author":"CK Mannesse","year":"2013","unstructured":"Mannesse CK, Jansen PA, Van Marum RJ, Sival RC, Kok RM, Haffmans PM, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357\u201363. https:\/\/doi.org\/10.1016\/j.maturitas.2013.08.010.","journal-title":"Maturitas"},{"issue":"50","key":"1506_CR75","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3238\/arztebl.2016.0855","volume":"113","author":"T Zieschang","year":"2016","unstructured":"Zieschang T, Wolf M, Vellappallil T, Uhlmann L, Oster P, Kopf D. The association of hyponatremia, risk of confusional state, and mortality. Dtsch Arztebl Int. 2016;113(50):855\u201362. https:\/\/doi.org\/10.3238\/arztebl.2016.0855.","journal-title":"Dtsch Arztebl Int"},{"issue":"2\u20133","key":"1506_CR76","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0014-2999(02)02557-8","volume":"454","author":"J Fujishiro","year":"2002","unstructured":"Fujishiro J, Imanishi T, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002;454(2\u20133):183\u20138. https:\/\/doi.org\/10.1016\/s0014-2999(02)02557-8.","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"1506_CR77","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1001\/jama.300.9.jrr80008","volume":"300","author":"JM Ellison","year":"2008","unstructured":"Ellison JM. A 60-year-old woman with mild memory impairment: review of mild cognitive impairment. JAMA. 2008;300(13):1566\u201374. https:\/\/doi.org\/10.1001\/jama.300.9.jrr80008.","journal-title":"JAMA"},{"issue":"2","key":"1506_CR78","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2013.06.030","volume":"151","author":"MM Herzallah","year":"2013","unstructured":"Herzallah MM, Moustafa AA, Natsheh JY, Danoun OA, Simon JR, Tayem YI, et al. Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder. J Affect Disord. 2013;151(2):484\u201392. https:\/\/doi.org\/10.1016\/j.jad.2013.06.030.","journal-title":"J Affect Disord"},{"issue":"3","key":"1506_CR79","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0028-3908(83)90238-1","volume":"22","author":"JZ Nowak","year":"1983","unstructured":"Nowak JZ, Arrang JM, Schwartz JC, Garbarg M. Interaction between mianserin, an antidepressant drug, and central H1- and H2-histamine-receptors: in vitro and in vivo studies and radioreceptor assay. Neuropharmacology. 1983;22(3):259\u201366. https:\/\/doi.org\/10.1016\/0028-3908(83)90238-1.","journal-title":"Neuropharmacology"},{"key":"1506_CR80","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/164_2018_167","volume":"250","author":"TE Schwasinger-Schmidt","year":"2019","unstructured":"Schwasinger-Schmidt TE, Macaluso M. Other antidepressants. Handb Exp Pharmacol. 2019;250:325\u201355. https:\/\/doi.org\/10.1007\/164_2018_167.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"1506_CR81","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/11319480-000000000-00000","volume":"24","author":"N Watanabe","year":"2010","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010;24(1):35\u201353. https:\/\/doi.org\/10.2165\/11319480-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"5","key":"1506_CR82","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/BF00635900","volume":"29","author":"HV Curran","year":"1986","unstructured":"Curran HV, Lader M. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. Eur J Clin Pharmacol. 1986;29(5):601\u20137. https:\/\/doi.org\/10.1007\/BF00635900.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"1506_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.2321","volume":"28","author":"K Sasada","year":"2013","unstructured":"Sasada K, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol. 2013;28(3):281\u20136. https:\/\/doi.org\/10.1002\/hup.2321.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"1506_CR84","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4088\/jcp.v66n0405","volume":"66","author":"M Wingen","year":"2005","unstructured":"Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005;66(4):436\u201343. https:\/\/doi.org\/10.4088\/jcp.v66n0405.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1506_CR85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.pbb.2011.01.020","volume":"99","author":"AF Arnsten","year":"2011","unstructured":"Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit\/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211\u20136. https:\/\/doi.org\/10.1016\/j.pbb.2011.01.020.","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"1506_CR86","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/1817-1745.199461","volume":"11","author":"S Jhanda","year":"2016","unstructured":"Jhanda S, Singla N, Grover S. Methylphenidate-induced obsessive-compulsive symptoms: a case report and review of literature. J Pediatr Neurosci. 2016;11(4):316\u20138. https:\/\/doi.org\/10.4103\/1817-1745.199461.","journal-title":"J Pediatr Neurosci"},{"issue":"1","key":"1506_CR87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/00004583-199401000-00023","volume":"33","author":"LK Jacobsen","year":"1994","unstructured":"Jacobsen LK, Chappell P, Woolston JL. Bupropion and compulsive behavior. J Am Acad Child Adolesc Psychiatry. 1994;33(1):143\u20134. https:\/\/doi.org\/10.1097\/00004583-199401000-00023.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"1506_CR88","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.1993.4","volume":"8","author":"DT Wong","year":"1993","unstructured":"Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8(1):23\u201333. https:\/\/doi.org\/10.1038\/npp.1993.4.","journal-title":"Neuropsychopharmacology"},{"issue":"24","key":"1506_CR89","first-page":"3033","volume":"51","author":"VL Ellingrod","year":"1994","unstructured":"Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm. 1994;51(24):3033\u201346.","journal-title":"Am J Hosp Pharm"},{"issue":"5","key":"1506_CR90","first-page":"519","volume":"155","author":"BA Liu","year":"1996","unstructured":"Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996;155(5):519\u201327.","journal-title":"CMAJ"},{"issue":"1","key":"1506_CR91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1099-1166(199801)13:1<12::AID-GPS718>3.0.CO;2-F","volume":"13","author":"WP Bouman","year":"1998","unstructured":"Bouman WP, Pinner G, Johnson H. Incidence of selective serotonin reuptake inhibitor (SSRI) induced hyponatraemia due to the syndrome of inappropriate antidiuretic hormone (SIADH) secretion in the elderly. Int J Geriatr Psychiatry. 1998;13(1):12\u20135.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"9","key":"1506_CR92","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/dtb.2022.000066","volume":"61","author":"D Bishara","year":"2023","unstructured":"Bishara D. Managing drugs with anticholinergic activity. Drug Ther Bull. 2023;61(9):135\u20139. https:\/\/doi.org\/10.1136\/dtb.2022.000066.","journal-title":"Drug Ther Bull"},{"key":"1506_CR93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neuropsychologia.2015.07.031","volume":"77","author":"SJ Fallon","year":"2015","unstructured":"Fallon SJ, Smulders K, Esselink RA, van de Warrenburg BP, Bloem BR, Cools R. Differential optimal dopamine levels for set-shifting and working memory in Parkinson\u2019s disease. Neuropsychologia. 2015;77:42\u201351. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2015.07.031.","journal-title":"Neuropsychologia"},{"issue":"11","key":"1506_CR94","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/sj.npp.1301167","volume":"31","author":"C Breitenstein","year":"2006","unstructured":"Breitenstein C, Korsukewitz C, Floel A, Kretzschmar T, Diederich K, Knecht S. Tonic dopaminergic stimulation impairs associative learning in healthy subjects. Neuropsychopharmacology. 2006;31(11):2552\u201364. https:\/\/doi.org\/10.1038\/sj.npp.1301167.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1506_CR95","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00213-007-0957-y","volume":"196","author":"DA Pizzagalli","year":"2008","unstructured":"Pizzagalli DA, Evins AE, Schetter EC, Frank MJ, Pajtas PE, Santesso DL, et al. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness. Psychopharmacology. 2008;196(2):221\u201332. https:\/\/doi.org\/10.1007\/s00213-007-0957-y.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1506_CR96","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1037\/0735-7044.120.3.497","volume":"120","author":"MJ Frank","year":"2006","unstructured":"Frank MJ, O\u2019Reilly RC. A mechanistic account of striatal dopamine function in human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav Neurosci. 2006;120(3):497\u2013517. https:\/\/doi.org\/10.1037\/0735-7044.120.3.497.","journal-title":"Behav Neurosci"},{"issue":"7","key":"1506_CR97","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1002\/hbm.20642","volume":"30","author":"DL Santesso","year":"2009","unstructured":"Santesso DL, Evins AE, Frank MJ, Schetter EC, Bogdan R, Pizzagalli DA. Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. Hum Brain Mapp. 2009;30(7):1963\u201376. https:\/\/doi.org\/10.1002\/hbm.20642.","journal-title":"Hum Brain Mapp"},{"issue":"4","key":"1506_CR98","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.neuropsychologia.2009.12.010","volume":"48","author":"M Jahanshahi","year":"2010","unstructured":"Jahanshahi M, Wilkinson L, Gahir H, Dharmaindra A, Lagnado DA. Medication impairs probabilistic classification learning in Parkinson\u2019s disease. Neuropsychologia. 2010;48(4):1096\u2013103. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2009.12.010.","journal-title":"Neuropsychologia"},{"issue":"7","key":"1506_CR99","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/j.1532-5415.1991.tb03627.x","volume":"39","author":"JL Cummings","year":"1991","unstructured":"Cummings JL. Behavioral complications of drug treatment of Parkinson\u2019s disease. J Am Geriatr Soc. 1991;39(7):708\u201316. https:\/\/doi.org\/10.1111\/j.1532-5415.1991.tb03627.x.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1506_CR100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcpt.12357","volume":"41","author":"N El-Saifi","year":"2016","unstructured":"El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther. 2016;41(1):7\u201318. https:\/\/doi.org\/10.1111\/jcpt.12357.","journal-title":"J Clin Pharm Ther"},{"key":"1506_CR101","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.euroneuro.2020.01.016","volume":"33","author":"F Dal Santo","year":"2020","unstructured":"Dal Santo F, Jarratt-Barnham I, Gonzalez-Blanco L, Garcia-Portilla MP, Bobes J, Fernandez-Egea E. Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: a mediation model. Eur Neuropsychopharmacol. 2020;33:158\u201363. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.01.016.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 13","key":"1506_CR102","first-page":"5","volume":"63","author":"CB Nemeroff","year":"2002","unstructured":"Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(Suppl 13):5\u201311.","journal-title":"J Clin Psychiatry"},{"key":"1506_CR103","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajp.2018.03.008","volume":"33","author":"SSR Mukku","year":"2018","unstructured":"Mukku SSR, Sivakumar PT, Varghese M. Clozapine use in geriatric patients\u2014challenges. Asian J Psychiatr. 2018;33:63\u20137. https:\/\/doi.org\/10.1016\/j.ajp.2018.03.008.","journal-title":"Asian J Psychiatr"},{"issue":"13","key":"1506_CR104","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1017\/S0033291717003774","volume":"48","author":"A Ballesteros","year":"2018","unstructured":"Ballesteros A, Sanchez-Torres AM, Lopez-Ilundain JM, Cabrera B, Lobo A, Gonzalez-Pinto AM, et al. Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis? Psychol Med. 2018;48(13):2247\u201356. https:\/\/doi.org\/10.1017\/S0033291717003774.","journal-title":"Psychol Med"},{"issue":"1","key":"1506_CR105","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00213-011-2471-5","volume":"220","author":"M Humbert-Claude","year":"2012","unstructured":"Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology. 2012;220(1):225\u201341. https:\/\/doi.org\/10.1007\/s00213-011-2471-5.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1506_CR106","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14656566.2024.2316135","volume":"25","author":"JH Friedman","year":"2024","unstructured":"Friedman JH. Parkinson\u2019s disease psychosis management: an evidence based, experience informed, pragmatic approach. Expert Opin Pharmacother. 2024;25(2):149\u201356. https:\/\/doi.org\/10.1080\/14656566.2024.2316135.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1506_CR107","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11065-018-9388-2","volume":"28","author":"JM Sheffield","year":"2018","unstructured":"Sheffield JM, Karcher NR, Barch DM. Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev. 2018;28(4):509\u201333. https:\/\/doi.org\/10.1007\/s11065-018-9388-2.","journal-title":"Neuropsychol Rev"},{"issue":"7","key":"1506_CR108","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1177\/0269881108100777","volume":"24","author":"D Elie","year":"2010","unstructured":"Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010;24(7):1037\u201344. https:\/\/doi.org\/10.1177\/0269881108100777.","journal-title":"J Psychopharmacol"},{"key":"1506_CR109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pharmthera.2018.06.012","volume":"192","author":"S Aringhieri","year":"2018","unstructured":"Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther. 2018;192:20\u201341. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.06.012.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1506_CR110","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1586\/ern.09.143","volume":"10","author":"SK Hill","year":"2010","unstructured":"Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010;10(1):43\u201357. https:\/\/doi.org\/10.1586\/ern.09.143.","journal-title":"Expert Rev Neurother"},{"key":"1506_CR111","volume-title":"Stahl's essential psychopharmacology : neuroscientific basis and practical application","author":"SM Stahl","year":"2013","unstructured":"Stahl SM. Stahl\u2019s essential psychopharmacology\u202f: neuroscientific basis and practical application. 4th ed. Cambridge: Cambridge University Press; 2013.","edition":"4"},{"key":"1506_CR112","doi-asserted-by":"publisher","first-page":"8213165","DOI":"10.1155\/2016\/8213165","volume":"2016","author":"M Rehse","year":"2016","unstructured":"Rehse M, Bartolovic M, Baum K, Richter D, Weisbrod M, Roesch-Ely D. Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. Schizophr Res Treatment. 2016;2016:8213165. https:\/\/doi.org\/10.1155\/2016\/8213165.","journal-title":"Schizophr Res Treatment."},{"issue":"Suppl 1","key":"1506_CR113","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.21037\/apm.2017.06.04","volume":"6","author":"D MacKintosh","year":"2017","unstructured":"MacKintosh D. Olanzapine induced delirium-a \u201cprobable\u201d adverse drug reaction. Ann Palliat Med. 2017;6(Suppl 1):S257\u20139. https:\/\/doi.org\/10.21037\/apm.2017.06.04.","journal-title":"Ann Palliat Med."},{"issue":"4","key":"1506_CR114","doi-asserted-by":"publisher","first-page":"582","DOI":"10.4088\/JCP.v65n0420d","volume":"65","author":"S Samuels","year":"2004","unstructured":"Samuels S, Fang M. Olanzapine may cause delirium in geriatric patients. J Clin Psychiatry. 2004;65(4):582\u20133.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1506_CR115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4306\/pi.2010.7.2.153","volume":"7","author":"RC Sharma","year":"2010","unstructured":"Sharma RC, Aggarwal A. Delirium associated with olanzapine therapy in an elderly male with bipolar affective disorder. Psychiatry Investig. 2010;7(2):153\u20134. https:\/\/doi.org\/10.4306\/pi.2010.7.2.153.","journal-title":"Psychiatry Investig"},{"key":"1506_CR116","doi-asserted-by":"publisher","first-page":"1358568","DOI":"10.3389\/fpsyt.2024.1358568","volume":"15","author":"H Cortes-Flores","year":"2024","unstructured":"Cortes-Flores H, Torrandell-Haro G, Brinton RD. Association between CNS-active drugs and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Front Psychiatry. 2024;15:1358568. https:\/\/doi.org\/10.3389\/fpsyt.2024.1358568.","journal-title":"Front Psychiatry."},{"key":"1506_CR117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-244X-13-109","volume":"13","author":"X Guo","year":"2013","unstructured":"Guo X, Zhang Z, Wei Q, Lv H, Wu R, Zhao J. The relationship between obesity and neurocognitive function in Chinese patients with schizophrenia. BMC Psychiatry. 2013;13:109. https:\/\/doi.org\/10.1186\/1471-244X-13-109.","journal-title":"BMC Psychiatry"},{"key":"1506_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100499","author":"SX Sui","year":"2020","unstructured":"Sui SX, Pasco JA. Obesity and brain function: the brain-body crosstalk. Medicina (Kaunas). 2020. https:\/\/doi.org\/10.3390\/medicina56100499.","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"1506_CR119","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jamapsychiatry.2020.0036","volume":"77","author":"AN Voineskos","year":"2020","unstructured":"Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, et al. Effects of antipsychotic medication on brain structure in patients with major depressive disorder and psychotic features: neuroimaging findings in the context of a randomized placebo-controlled clinical trial. JAMA Psychiat. 2020;77(7):674\u201383. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.0036.","journal-title":"JAMA Psychiat"},{"issue":"3","key":"1506_CR120","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1001\/jamapsychiatry.2014.2178","volume":"72","author":"TA Lesh","year":"2015","unstructured":"Lesh TA, Tanase C, Geib BR, Niendam TA, Yoon JH, Minzenberg MJ, et al. A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiat. 2015;72(3):226\u201334. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2178.","journal-title":"JAMA Psychiat"},{"key":"1506_CR121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pscychresns.2018.10.001","volume":"282","author":"PB Gjerde","year":"2018","unstructured":"Gjerde PB, Jorgensen KN, Steen NE, Melle I, Andreassen OA, Steen VM, et al. Association between olanzapine treatment and brain cortical thickness and gray\/white matter contrast is moderated by cholesterol in psychotic disorders. Psychiatry Res Neuroimaging. 2018;282:55\u201363. https:\/\/doi.org\/10.1016\/j.pscychresns.2018.10.001.","journal-title":"Psychiatry Res Neuroimaging."},{"issue":"9","key":"1506_CR122","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.biopsych.2018.04.023","volume":"84","author":"TGM van Erp","year":"2018","unstructured":"van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, et al. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium. Biol Psychiatry. 2018;84(9):644\u201354. https:\/\/doi.org\/10.1016\/j.biopsych.2018.04.023.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1506_CR123","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41398-020-0828-4","volume":"10","author":"N Liu","year":"2020","unstructured":"Liu N, Xiao Y, Zhang W, Tang B, Zeng J, Hu N, et al. Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients. Transl Psychiatry. 2020;10(1):136. https:\/\/doi.org\/10.1038\/s41398-020-0828-4.","journal-title":"Transl Psychiatry"},{"key":"1506_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.749316","volume":"15","author":"Y Chen","year":"2021","unstructured":"Chen Y, Womer FY, Feng R, Zhang X, Zhang Y, Duan J, et al. A real-world observation of antipsychotic effects on brain volumes and intrinsic brain activity in schizophrenia. Front Neurosci. 2021;15: 749316. https:\/\/doi.org\/10.3389\/fnins.2021.749316.","journal-title":"Front Neurosci"},{"key":"1506_CR125","doi-asserted-by":"publisher","first-page":"1127353","DOI":"10.3389\/fpsyt.2023.1127353","volume":"14","author":"X Zong","year":"2023","unstructured":"Zong X, Wang G, Nie Z, Ma S, Kang L, Zhang N, et al. Longitudinal multi-omics alterations response to 8-week risperidone monotherapy: evidence linking cortical thickness, transcriptomics and epigenetics. Front Psychiatry. 2023;14:1127353. https:\/\/doi.org\/10.3389\/fpsyt.2023.1127353.","journal-title":"Front Psychiatry."},{"issue":"9","key":"1506_CR126","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/archgenpsychiatry.2011.88","volume":"68","author":"NE van Haren","year":"2011","unstructured":"van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, et al. Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry. 2011;68(9):871\u201380. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.88.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1506_CR127","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/pharmrev.120.000007","volume":"76","author":"A Bortolozzi","year":"2024","unstructured":"Bortolozzi A, Fico G, Berk M, Solmi M, Fornaro M, Quevedo J, et al. New advances in the pharmacology and toxicology of lithium: a neurobiologically oriented overview. Pharmacol Rev. 2024;76(3):323\u201357. https:\/\/doi.org\/10.1124\/pharmrev.120.000007.","journal-title":"Pharmacol Rev"},{"issue":"9817","key":"1506_CR128","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","volume":"379","author":"RF McKnight","year":"2012","unstructured":"McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(11)61516-X.","journal-title":"Lancet"},{"issue":"11","key":"1506_CR129","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.4088\/JCP.08r04972","volume":"70","author":"AP Wingo","year":"2009","unstructured":"Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ. Effects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry. 2009;70(11):1588\u201397. https:\/\/doi.org\/10.4088\/JCP.08r04972.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"1506_CR130","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50225","volume":"15","author":"NN Kronk","year":"2023","unstructured":"Kronk NN, Kronk BK, Robbie AT. A case report: lithium-induced neurotoxicity, a differential to always consider. Cureus. 2023;15(12): e50225. https:\/\/doi.org\/10.7759\/cureus.50225.","journal-title":"Cureus."},{"key":"1506_CR131","doi-asserted-by":"publisher","first-page":"8052471","DOI":"10.1155\/2022\/8052471","volume":"2022","author":"C Carmassi","year":"2022","unstructured":"Carmassi C, Nardi B, Battaglini S, Bonelli C, Violi M, Bonanni E, et al. A case of lithium encephalopathy with therapeutic lithium levels: the diagnostic role of EEG. Case Rep Psychiatry. 2022;2022:8052471. https:\/\/doi.org\/10.1155\/2022\/8052471.","journal-title":"Case Rep Psychiatry."},{"key":"1506_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-207646","author":"A Evrensel","year":"2014","unstructured":"Evrensel A, Unsalver BO, Ceylan ME, Comert G. Lithium-induced cortical atrophy and cognitive dysfunction. BMJ Case Rep. 2014. https:\/\/doi.org\/10.1136\/bcr-2014-207646.","journal-title":"BMJ Case Rep"},{"issue":"8290","key":"1506_CR133","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/s0140-6736(82)91130-8","volume":"2","author":"G Hay","year":"1982","unstructured":"Hay G, Simpson N. Neurotoxicity associated with therapeutic serum lithium levels. Lancet. 1982;2(8290):160\u20131. https:\/\/doi.org\/10.1016\/s0140-6736(82)91130-8.","journal-title":"Lancet"},{"issue":"2","key":"1506_CR134","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/01.pra.0000462608.02478.16","volume":"21","author":"J Soriano-Barcelo","year":"2015","unstructured":"Soriano-Barcelo J, Alonso MT, Traba MB, Vilar AA, Kahn DA. A case with reversible neurotoxicity after 2 years of dementia secondary to maintenance lithium treatment. J Psychiatr Pract. 2015;21(2):154\u20139. https:\/\/doi.org\/10.1097\/01.pra.0000462608.02478.16.","journal-title":"J Psychiatr Pract"},{"issue":"5","key":"1506_CR135","first-page":"169","volume":"33","author":"J Gallinat","year":"2000","unstructured":"Gallinat J, Boetsch T, Padberg F, Hampel H, Herrmann WM, Hegerl U. Is the EEG helpful in diagnosing and monitoring lithium intoxication? A case report and review of the literature. Pharmacopsychiatry. 2000;33(5):169\u201373.","journal-title":"Pharmacopsychiatry"},{"key":"1506_CR136","doi-asserted-by":"publisher","first-page":"204512532090573","DOI":"10.1177\/2045125320905734","volume":"10","author":"J Valtonen","year":"2020","unstructured":"Valtonen J, Karrasch M. Polypharmacy-induced cognitive dysfunction and discontinuation of psychotropic medication: a neuropsychological case report. Ther Adv Psychopharmacol. 2020;10:2045125320905734. https:\/\/doi.org\/10.1177\/2045125320905734.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"Suppl","key":"1506_CR137","first-page":"7","volume":"53","author":"DJ Greenblatt","year":"1992","unstructured":"Greenblatt DJ. Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry. 1992;53(Suppl):7\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1506_CR138","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00002018-200326040-00004","volume":"26","author":"MG Terzano","year":"2003","unstructured":"Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261\u201382. https:\/\/doi.org\/10.2165\/00002018-200326040-00004.","journal-title":"Drug Saf"},{"issue":"1","key":"1506_CR139","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1176\/ajp.144.1.25","volume":"144","author":"OM Wolkowitz","year":"1987","unstructured":"Wolkowitz OM, Weingartner H, Thompson K, Pickar D, Paul SM, Hommer DW. Diazepam-induced amnesia: a neuropharmacological model of an \u201corganic amnestic syndrome.\u201d Am J Psychiatry. 1987;144(1):25\u20139. https:\/\/doi.org\/10.1176\/ajp.144.1.25.","journal-title":"Am J Psychiatry"},{"key":"1506_CR140","first-page":"146","volume":"6","author":"CA O'Boyle","year":"1988","unstructured":"O\u2019Boyle CA. Benzodiazepine-induced amnesia and anaesthetic practice: a review. Psychopharmacol Ser. 1988;6:146\u201365.","journal-title":"Psychopharmacol Ser"},{"issue":"Suppl 2","key":"1506_CR141","first-page":"9","volume":"66","author":"SA Stewart","year":"2005","unstructured":"Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1506_CR142","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0009-9236(98)90059-5","volume":"64","author":"JT Hanlon","year":"1998","unstructured":"Hanlon JT, Horner RD, Schmader KE, Fillenbaum GG, Lewis IK, Wall WE Jr, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998;64(6):684\u201392. https:\/\/doi.org\/10.1016\/S0009-9236(98)90059-5.","journal-title":"Clin Pharmacol Ther"},{"key":"1506_CR143","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.595623","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Jian P, Zhou Y, Zhou J, Jia L, Tang M, et al. Is the long-term use of benzodiazepines associated with worse cognition performance in highly educated older adults? Front Psychiatry. 2020;11: 595623. https:\/\/doi.org\/10.3389\/fpsyt.2020.595623.","journal-title":"Front Psychiatry."},{"issue":"3","key":"1506_CR144","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3233\/JAD-180745","volume":"66","author":"Z Kurlawala","year":"2018","unstructured":"Kurlawala Z, Roberts JA, McMillan JD, Friedland RP. Diazepam toxicity presenting as a dementia disorder. J Alzheimers Dis. 2018;66(3):935\u20138. https:\/\/doi.org\/10.3233\/JAD-180745.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"1506_CR145","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/gps.1811","volume":"22","author":"EJ Bierman","year":"2007","unstructured":"Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry. 2007;22(12):1194\u2013200. https:\/\/doi.org\/10.1002\/gps.1811.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"1506_CR146","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s41999-021-00553-w","volume":"13","author":"P Ferreira","year":"2022","unstructured":"Ferreira P, Ferreira AR, Barreto B, Fernandes L. Is there a link between the use of benzodiazepines and related drugs and dementia? A systematic review of reviews. Eur Geriatr Med. 2022;13(1):19\u201332. https:\/\/doi.org\/10.1007\/s41999-021-00553-w.","journal-title":"Eur Geriatr Med."},{"issue":"6","key":"1506_CR147","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1213\/ANE.0000000000005959","volume":"134","author":"MS Duprey","year":"2022","unstructured":"Duprey MS, Devlin JW, Griffith JL, Travison TG, Briesacher BA, Jones R, et al. Association between perioperative medication use and postoperative delirium and cognition in older adults undergoing elective noncardiac surgery. Anesth Analg. 2022;134(6):1154\u201363. https:\/\/doi.org\/10.1213\/ANE.0000000000005959.","journal-title":"Anesth Analg"},{"issue":"4","key":"1506_CR148","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200443040-00002","volume":"43","author":"DR Drover","year":"2004","unstructured":"Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43(4):227\u201338. https:\/\/doi.org\/10.2165\/00003088-200443040-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1506_CR149","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/pm\/pnac113","volume":"24","author":"NS Warner","year":"2023","unstructured":"Warner NS, Mielke MM, Verdoorn BP, Knopman DS, Hooten WM, Habermann EB, et al. Pain, opioid analgesics, and cognition: a conceptual framework in older adults. Pain Med. 2023;24(2):171\u201381. https:\/\/doi.org\/10.1093\/pm\/pnac113.","journal-title":"Pain Med"},{"issue":"1","key":"1506_CR150","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11916-008-0007-4","volume":"12","author":"SA Strassels","year":"2008","unstructured":"Strassels SA. Cognitive effects of opioids. Curr Pain Headache Rep. 2008;12(1):32\u20136. https:\/\/doi.org\/10.1007\/s11916-008-0007-4.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1506_CR151","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/J354v21n01_05","volume":"21","author":"J Vella-Brincat","year":"2007","unstructured":"Vella-Brincat J, Macleod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother. 2007;21(1):15\u201325.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"1506_CR152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/15389588.2012.689451","volume":"14","author":"MC Strand","year":"2013","unstructured":"Strand MC, Fjeld B, Arnestad M, Morland J. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration. Traffic Inj Prev. 2013;14(1):26\u201338. https:\/\/doi.org\/10.1080\/15389588.2012.689451.","journal-title":"Traffic Inj Prev"},{"issue":"2","key":"1506_CR153","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/psyg.12007","volume":"13","author":"G Ito","year":"2013","unstructured":"Ito G, Kanemoto K. A case of topical opioid-induced delirium mistaken as behavioural and psychological symptoms of dementia in demented state. Psychogeriatrics. 2013;13(2):118\u201323. https:\/\/doi.org\/10.1111\/psyg.12007.","journal-title":"Psychogeriatrics"},{"issue":"2","key":"1506_CR154","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00701-023-05486-w","volume":"165","author":"VM Butenschoen","year":"2023","unstructured":"Butenschoen VM, Wriedt F, Meyer B, Krieg SM. Neurocognitive monitoring in patients undergoing opioid pain medication after spinal surgery: a feasibility study of a new monitoring method. Acta Neurochir (Wien). 2023;165(2):335\u201340. https:\/\/doi.org\/10.1007\/s00701-023-05486-w.","journal-title":"Acta Neurochir (Wien)"},{"issue":"11","key":"1506_CR155","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/JOM.0000000000001154","volume":"59","author":"M Kowalski-McGraw","year":"2017","unstructured":"Kowalski-McGraw M, Green-McKenzie J, Pandalai SP, Schulte PA. Characterizing the interrelationships of prescription opioid and benzodiazepine drugs with worker health and workplace hazards. J Occup Environ Med. 2017;59(11):1114\u201326. https:\/\/doi.org\/10.1097\/JOM.0000000000001154.","journal-title":"J Occup Environ Med"},{"key":"1506_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117048","volume":"417","author":"JA Barash","year":"2020","unstructured":"Barash JA, Whitledge J, Watson CJ, Boyle K, Lim C, Lev MH, et al. Opioid-associated amnestic syndrome: description of the syndrome and validation of a proposed definition. J Neurol Sci. 2020;417: 117048. https:\/\/doi.org\/10.1016\/j.jns.2020.117048.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1506_CR157","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20056","volume":"13","author":"ML Walker","year":"2021","unstructured":"Walker ML, Patel K, Li T, Kassir M. Opioid-associated amnestic syndrome. Cureus. 2021;13(11): e20056. https:\/\/doi.org\/10.7759\/cureus.20056.","journal-title":"Cureus."},{"issue":"8","key":"1506_CR158","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44248","volume":"15","author":"E McConnell","year":"2023","unstructured":"McConnell E, Bai J. Hippocampal and cerebellar involvement in opioid-associated amnestic syndrome: a unique case report. Cureus. 2023;15(8): e44248. https:\/\/doi.org\/10.7759\/cureus.44248.","journal-title":"Cureus."},{"issue":"3","key":"1506_CR159","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1515\/revneuro.1995.6.3.279","volume":"6","author":"TJ Grudt","year":"1995","unstructured":"Grudt TJ, Williams JT. Opioid receptors and the regulation of ion conductances. Rev Neurosci. 1995;6(3):279\u201386. https:\/\/doi.org\/10.1515\/revneuro.1995.6.3.279.","journal-title":"Rev Neurosci"},{"key":"1506_CR160","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-540-33823-9_2","volume":"177","author":"C Zollner","year":"2007","unstructured":"Zollner C, Stein C. Opioids. Handb Exp Pharmacol. 2007;177:31\u201363. https:\/\/doi.org\/10.1007\/978-3-540-33823-9_2.","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"1506_CR161","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1097\/00000539-200211000-00031","volume":"95","author":"Y Shiga","year":"2002","unstructured":"Shiga Y, Minami K, Shiraishi M, Uezono Y, Murasaki O, Kaibara M, et al. The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors. Anesth Analg. 2002;95(5):1269\u201373. https:\/\/doi.org\/10.1097\/00000539-200211000-00031.","journal-title":"Anesth Analg"},{"issue":"3","key":"1506_CR162","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/npr2.12188","volume":"41","author":"SH Hassaan","year":"2021","unstructured":"Hassaan SH, Khalifa H, Darwish AM. Effects of extended abstinence on cognitive functions in tramadol-dependent patients: a cohort study. Neuropsychopharmacol Rep. 2021;41(3):371\u20138. https:\/\/doi.org\/10.1002\/npr2.12188.","journal-title":"Neuropsychopharmacol Rep."},{"key":"1506_CR163","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fphar.2017.00254","volume":"8","author":"V Bortolotto","year":"2017","unstructured":"Bortolotto V, Grilli M. Opiate analgesics as negative modulators of adult hippocampal neurogenesis: potential implications in clinical practice. Front Pharmacol. 2017;8:254. https:\/\/doi.org\/10.3389\/fphar.2017.00254.","journal-title":"Front Pharmacol"},{"issue":"17","key":"1506_CR164","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1523\/JNEUROSCI.22-17-07650.2002","volume":"22","author":"J Mao","year":"2002","unstructured":"Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci. 2002;22(17):7650\u201361. https:\/\/doi.org\/10.1523\/JNEUROSCI.22-17-07650.2002.","journal-title":"J Neurosci"},{"issue":"1","key":"1506_CR165","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1038\/s41598-024-53728-3","volume":"14","author":"TK Oh","year":"2024","unstructured":"Oh TK, Song IA. Impact of prescribed opioid use on development of dementia among patients with chronic non-cancer pain. Sci Rep. 2024;14(1):3313. https:\/\/doi.org\/10.1038\/s41598-024-53728-3.","journal-title":"Sci Rep"},{"issue":"5","key":"1506_CR166","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jagp.2022.05.013","volume":"31","author":"SZ Levine","year":"2023","unstructured":"Levine SZ, Rotstein A, Goldberg Y, Reichenberg A, Kodesh A. Opioid exposure and the risk of dementia: a national cohort study. Am J Geriatr Psychiatry. 2023;31(5):315\u201323. https:\/\/doi.org\/10.1016\/j.jagp.2022.05.013.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"1506_CR167","doi-asserted-by":"publisher","first-page":"109","DOI":"10.36076\/ppj.2014\/17\/109","volume":"17","author":"G Jain","year":"2014","unstructured":"Jain G, Mahendra V, Singhal S, Dzara K, Pilla TR, Manworren R, et al. Long-term neuropsychological effects of opioid use in children: a descriptive literature review. Pain Physician. 2014;17(2):109\u201318.","journal-title":"Pain Physician"},{"key":"1506_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.04.010","author":"Y Gao","year":"2024","unstructured":"Gao Y, Su B, Ding L, Qureshi D, Hong S, Wei J, et al. Association of regular opioid use with incident dementia and neuroimaging markers of brain health in chronic pain patients: analysis of UK biobank. Am J Geriatr Psychiatry. 2024. https:\/\/doi.org\/10.1016\/j.jagp.2024.04.010.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"Suppl. 22","key":"1506_CR169","doi-asserted-by":"publisher","DOI":"10.1002\/alz.077103","volume":"19","author":"C Jensen-Dahm","year":"2023","unstructured":"Jensen-Dahm C, Janbek J, Gasse C, Munk Laurssen T, Waldemar G. Excessive mortality risk associated with new opioid use in older people with dementia. Alzheimers Dement. 2023;19(Suppl. 22): e077103. https:\/\/doi.org\/10.1002\/alz.077103.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1506_CR170","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2014.7663.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1506_CR171","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","volume":"4","author":"M Boustani","year":"2008","unstructured":"Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311\u201320.","journal-title":"Aging Health"},{"issue":"1\u20133","key":"1506_CR172","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ejphar.2008.12.043","volume":"605","author":"A McNamara","year":"2009","unstructured":"McNamara A, Pulido-Rios MT, Sweazey S, Obedencio GP, Thibodeaux H, Renner T, et al. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist. Eur J Pharmacol. 2009;605(1\u20133):145\u201352. https:\/\/doi.org\/10.1016\/j.ejphar.2008.12.043.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1506_CR173","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12877-023-04095-7","volume":"23","author":"IB Poonawalla","year":"2023","unstructured":"Poonawalla IB, Xu Y, Gaddy R, James A, Ruble M, Burns S, et al. Anticholinergic exposure and its association with dementia\/Alzheimer\u2019s disease and mortality in older adults. BMC Geriatr. 2023;23(1):401. https:\/\/doi.org\/10.1186\/s12877-023-04095-7.","journal-title":"BMC Geriatr"},{"key":"1506_CR174","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/cia.s5358","volume":"4","author":"N Campbell","year":"2009","unstructured":"Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225\u201333. https:\/\/doi.org\/10.2147\/cia.s5358.","journal-title":"Clin Interv Aging"},{"issue":"5","key":"1506_CR175","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/ageing\/afu096","volume":"43","author":"C Fox","year":"2014","unstructured":"Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43(5):604\u201315. https:\/\/doi.org\/10.1093\/ageing\/afu096.","journal-title":"Age Ageing"},{"issue":"11","key":"1506_CR176","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","volume":"18","author":"B Welk","year":"2021","unstructured":"Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18(11):686\u2013700. https:\/\/doi.org\/10.1038\/s41585-021-00504-x.","journal-title":"Nat Rev Urol"},{"key":"1506_CR177","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1315","volume":"361","author":"K Richardson","year":"2018","unstructured":"Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361: k1315. https:\/\/doi.org\/10.1136\/bmj.k1315.","journal-title":"BMJ"},{"issue":"8","key":"1506_CR178","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/03007995.2021.1920899","volume":"37","author":"N Kachru","year":"2021","unstructured":"Kachru N, Holmes HM, Johnson ML, Chen H, Aparasu RR. Antimuscarinic use among older adults with dementia and overactive bladder: a medicare beneficiaries study. Curr Med Res Opin. 2021;37(8):1303\u201313. https:\/\/doi.org\/10.1080\/03007995.2021.1920899.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1506_CR179","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling TL, Campbell NL, Mangel J, Staskin D, Herschorn S, Elsouda D, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109. https:\/\/doi.org\/10.1186\/s12877-020-1474-7.","journal-title":"BMC Geriatr"},{"issue":"6","key":"1506_CR180","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1046\/j.1532-5415.2002.50281.x","volume":"50","author":"KR Edwards","year":"2002","unstructured":"Edwards KR, O\u2019Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc. 2002;50(6):1165\u20136. https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50281.x.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1506_CR181","first-page":"291","volume":"71","author":"PJ Zed","year":"2018","unstructured":"Zed PJ. Deprescribing proton pump inhibitors. Can J Hosp Pharm. 2018;71(5):291\u20132.","journal-title":"Can J Hosp Pharm"},{"issue":"18","key":"1506_CR182","doi-asserted-by":"publisher","first-page":"e1771","DOI":"10.1212\/WNL.0000000000207747","volume":"101","author":"CA Northuis","year":"2023","unstructured":"Northuis CA, Bell EJ, Lutsey PL, George KM, Gottesman RF, Mosley TH, et al. Cumulative use of proton pump inhibitors and risk of dementia: the atherosclerosis risk in communities study. Neurology. 2023;101(18):e1771\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000207747.","journal-title":"Neurology"},{"issue":"4","key":"1506_CR183","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.trci.2017.08.007","volume":"3","author":"SAP Clouston","year":"2017","unstructured":"Clouston SAP, Shapira O, Kotov R, Lei L, Waszczuk M, Bromet EJ, et al. Proton pump inhibitors and the risk of severe cognitive impairment: the role of posttraumatic stress disorder. Alzheimers Dement (N Y). 2017;3(4):579\u201383. https:\/\/doi.org\/10.1016\/j.trci.2017.08.007.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"4","key":"1506_CR184","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","volume":"73","author":"W Gomm","year":"2016","unstructured":"Gomm W, von Holt K, Thome F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410\u20136. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4791.","journal-title":"JAMA Neurol"},{"issue":"2","key":"1506_CR185","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171006","volume":"12","author":"SY Tai","year":"2017","unstructured":"Tai SY, Chien CY, Wu DC, Lin KD, Ho BL, Chang YH, et al. Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS\u00a0One. 2017;12(2): e0171006. https:\/\/doi.org\/10.1371\/journal.pone.0171006.","journal-title":"PLoS\u00a0One"},{"issue":"7","key":"1506_CR186","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40266-023-01031-7","volume":"40","author":"N Ahn","year":"2023","unstructured":"Ahn N, Wawro N, Baumeister SE, Nolde M, Gerlach R, Tauscher M, et al. Time-varying use of proton pump inhibitors and cognitive impairment and dementia: a real-world analysis from Germany. Drugs Aging. 2023;40(7):653\u201363. https:\/\/doi.org\/10.1007\/s40266-023-01031-7.","journal-title":"Drugs Aging"},{"issue":"7","key":"1506_CR187","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/alz.12113","volume":"16","author":"R Kumar","year":"2020","unstructured":"Kumar R, Kumar A, Nordberg A, Langstrom B, Darreh-Shori T. Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme-A plausible missing link for their association with incidence of dementia. Alzheimers Dement. 2020;16(7):1031\u201342. https:\/\/doi.org\/10.1002\/alz.12113.","journal-title":"Alzheimers Dement"},{"issue":"22","key":"1506_CR188","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.2013.280490","volume":"310","author":"JR Lam","year":"2013","unstructured":"Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435\u201342. https:\/\/doi.org\/10.1001\/jama.2013.280490.","journal-title":"JAMA"},{"issue":"11","key":"1506_CR189","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31672","volume":"14","author":"KM Swarnakari","year":"2022","unstructured":"Swarnakari KM, Bai M, Manoharan MP, Raja R, Jamil A, Csendes D, et al. The effects of proton pump inhibitors in acid hypersecretion-induced Vitamin B12 deficiency: a systematic review (2022). Cureus. 2022;14(11): e31672. https:\/\/doi.org\/10.7759\/cureus.31672.","journal-title":"Cureus."},{"key":"1506_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/biom12010129","author":"AA Lauer","year":"2022","unstructured":"Lauer AA, Grimm HS, Apel B, Golobrodska N, Kruse L, Ratanski E, et al. Mechanistic link between Vitamin B12 and Alzheimer\u2019s disease. Biomolecules. 2022. https:\/\/doi.org\/10.3390\/biom12010129.","journal-title":"Biomolecules"},{"issue":"3","key":"1506_CR191","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.therap.2017.08.003","volume":"73","author":"F Kheloufi","year":"2018","unstructured":"Kheloufi F, Frankel D, Kaspi E, Lepelley M, Mallaret M, Boucherie Q, et al. Chronic use of proton pump inhibitors, adverse events and potential biological mechanisms: a translational analysis. Therapie. 2018;73(3):273\u201381. https:\/\/doi.org\/10.1016\/j.therap.2017.08.003.","journal-title":"Therapie"},{"issue":"2","key":"1506_CR192","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S0022-3565(24)34931-6","volume":"290","author":"I Puscas","year":"1999","unstructured":"Puscas I, Coltau M, Baican M, Domuta G. Omeprazole has a dual mechanism of action: it inhibits both H(+)K(+)ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J Pharmacol Exp Ther. 1999;290(2):530\u20134.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1506_CR193","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s0920-1211(01)00262-5","volume":"46","author":"S Balakrishnan","year":"2001","unstructured":"Balakrishnan S, Bhargava VK, Pandhi P. Anticonvulsant activity of omeprazole in rats. Epilepsy Res. 2001;46(1):85\u20139. https:\/\/doi.org\/10.1016\/s0920-1211(01)00262-5.","journal-title":"Epilepsy Res"},{"key":"1506_CR194","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082544","author":"V Poggetti","year":"2022","unstructured":"Poggetti V, Salerno S, Baglini E, Barresi E, Da Settimo F, Taliani S. Carbonic anhydrase activators for neurodegeneration: an overview. Molecules. 2022. https:\/\/doi.org\/10.3390\/molecules27082544.","journal-title":"Molecules"},{"issue":"40","key":"1506_CR195","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000039729","volume":"103","author":"W Zhao","year":"2024","unstructured":"Zhao W, Zhang J, Jia H, He Q, Cui J, Ding L, et al. Proton pump inhibitor-induced hypomagnesemia, a rare cause of reversible delirium: a case report with literature review. Medicine (Baltimore). 2024;103(40): e39729. https:\/\/doi.org\/10.1097\/MD.0000000000039729.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1506_CR196","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s004150050011","volume":"247","author":"JG Heckmann","year":"2000","unstructured":"Heckmann JG, Birklein F, Neundorfer B. Omeprazole-induced delirium. J Neurol. 2000;247(1):56\u20137. https:\/\/doi.org\/10.1007\/s004150050011.","journal-title":"J Neurol"},{"key":"1506_CR197","doi-asserted-by":"publisher","first-page":"1232535","DOI":"10.1155\/2018\/1232535","volume":"2018","author":"A Razdan","year":"2018","unstructured":"Razdan A, Viswanathan R, Tusher A. Pantoprazole-induced delirium: review of a case and associated literature. Case Rep Psychiatry. 2018;2018:1232535. https:\/\/doi.org\/10.1155\/2018\/1232535.","journal-title":"Case Rep Psychiatry."},{"key":"1506_CR198","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CIA.S103349","volume":"11","author":"I Otremba","year":"2016","unstructured":"Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging. 2016;11:397\u2013405. https:\/\/doi.org\/10.2147\/CIA.S103349.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1506_CR199","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00004728-197801000-00003","volume":"2","author":"J Bentson","year":"1978","unstructured":"Bentson J, Reza M, Winter J, Wilson G. Steroids and apparent cerebral atrophy on computed tomography scans. J Comput Assist Tomogr. 1978;2(1):16\u201323. https:\/\/doi.org\/10.1097\/00004728-197801000-00003.","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"1506_CR200","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00004728-198002000-00004","volume":"4","author":"T Okuno","year":"1980","unstructured":"Okuno T, Ito M, Konishi Y, Yoshioka M, Nakano Y. Cerebral atrophy following ACTH therapy. J Comput Assist Tomogr. 1980;4(1):20\u20133. https:\/\/doi.org\/10.1097\/00004728-198002000-00004.","journal-title":"J Comput Assist Tomogr"},{"issue":"5 Pt 1","key":"1506_CR201","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1523\/JNEUROSCI.14-05-02893.1994","volume":"14","author":"S Lupien","year":"1994","unstructured":"Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NP, Meaney MJ. Basal cortisol levels and cognitive deficits in human aging. J Neurosci. 1994;14(5 Pt 1):2893\u2013903. https:\/\/doi.org\/10.1523\/JNEUROSCI.14-05-02893.1994.","journal-title":"J Neurosci"},{"issue":"5","key":"1506_CR202","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1006\/smns.1994.1041","volume":"6","author":"RM Sapolsky","year":"1994","unstructured":"Sapolsky RM. Glucocorticoids, stress and exacerbation of excitotoxic neuron death. Seminars Neurosci. 1994;6(5):323\u201331. https:\/\/doi.org\/10.1006\/smns.1994.1041.","journal-title":"Seminars Neurosci."},{"key":"1506_CR203","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1749-6632.1995.tb31402.x","volume":"761","author":"PA Keenan","year":"1995","unstructured":"Keenan PA, Jacobson MW, Soleymani RM, Newcomer JW. Commonly used therapeutic doses of glucocorticoids impair explicit memory. Ann N Y Acad Sci. 1995;761:400\u20132. https:\/\/doi.org\/10.1111\/j.1749-6632.1995.tb31402.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"1506_CR204","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s40618-023-02091-7","volume":"46","author":"D De Alcubierre","year":"2023","unstructured":"De Alcubierre D, Ferrari D, Mauro G, Isidori AM, Tomlinson JW, Pofi R. Glucocorticoids and cognitive function: a walkthrough in endogenous and exogenous alterations. J Endocrinol Invest. 2023;46(10):1961\u201382. https:\/\/doi.org\/10.1007\/s40618-023-02091-7.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1506_CR205","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2003.09.010","volume":"55","author":"ES Brown","year":"2004","unstructured":"Brown ES, D JW, Frol A, Bobadilla L, Khan DA, Hanczyc M, et al. Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy. Biol Psychiatry. 2004;55(5):538\u201345. https:\/\/doi.org\/10.1016\/j.biopsych.2003.09.010.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1506_CR206","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1017\/S1355617712001014","volume":"19","author":"C Mrakotsky","year":"2013","unstructured":"Mrakotsky C, Forbes PW, Bernstein JH, Grand RJ, Bousvaros A, Szigethy E, et al. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. J Int Neuropsychol Soc. 2013;19(1):96\u2013109. https:\/\/doi.org\/10.1017\/S1355617712001014.","journal-title":"J Int Neuropsychol Soc"},{"issue":"3","key":"1506_CR207","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1176\/ajp.141.3.369","volume":"141","author":"NR Varney","year":"1984","unstructured":"Varney NR, Alexander B, MacIndoe JH. Reversible steroid dementia in patients without steroid psychosis. Am J Psychiatry. 1984;141(3):369\u201372. https:\/\/doi.org\/10.1176\/ajp.141.3.369.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1506_CR208","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/arclin\/12.2.167","volume":"12","author":"NR Varney","year":"1997","unstructured":"Varney NR. A case of reversible steroid dementia. Arch Clin Neuropsychol. 1997;12(2):167\u201371.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"1506_CR209","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1212\/01.wnl.0000203713.04232.82","volume":"66","author":"C Norra","year":"2006","unstructured":"Norra C, Arndt M, Kunert HJ. Steroid dementia: an overlooked diagnosis? Neurology. 2006;66(1):155. https:\/\/doi.org\/10.1212\/01.wnl.0000203713.04232.82.","journal-title":"Neurology"},{"key":"1506_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2023.109314","volume":"200","author":"L Spannenburg","year":"2023","unstructured":"Spannenburg L, Reed H. Adverse cognitive effects of glucocorticoids: a systematic review of the literature. Steroids. 2023;200: 109314. https:\/\/doi.org\/10.1016\/j.steroids.2023.109314.","journal-title":"Steroids"},{"issue":"6","key":"1506_CR211","doi-asserted-by":"publisher","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","volume":"109","author":"A Koning","year":"2024","unstructured":"Koning A, van der Meulen M, Schaap D, Satoer DD, Vinkers CH, van Rossum EFC, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(6):e1442\u201351. https:\/\/doi.org\/10.1210\/clinem\/dgad701.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1506_CR212","doi-asserted-by":"publisher","first-page":"300060522112666","DOI":"10.1177\/03000605221126660","volume":"50","author":"J Finsterer","year":"2022","unstructured":"Finsterer J. Transient tunnel vision and altered consciousness after a single dose of ibuprofen. J Int Med Res. 2022;50(9):3000605221126660. https:\/\/doi.org\/10.1177\/03000605221126660.","journal-title":"J Int Med Res"},{"issue":"1","key":"1506_CR213","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1345\/aph.1C218","volume":"37","author":"AL Bernstein","year":"2003","unstructured":"Bernstein AL, Werlin A. Pseudodementia associated with use of ibuprofen. Ann Pharmacother. 2003;37(1):80\u20132. https:\/\/doi.org\/10.1345\/aph.1C218.","journal-title":"Ann Pharmacother"},{"issue":"22","key":"1506_CR214","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1212\/WNL.0b013e3181a18691","volume":"72","author":"JC Breitner","year":"2009","unstructured":"Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899\u2013905. https:\/\/doi.org\/10.1212\/WNL.0b013e3181a18691.","journal-title":"Neurology"},{"issue":"21","key":"1506_CR215","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMoa010178","volume":"345","author":"BA in t, Veld","year":"2001","unstructured":"in t, Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer\u2019s disease. N Engl J Med. 2001;345(21):1515\u201321. https:\/\/doi.org\/10.1056\/NEJMoa010178.","journal-title":"N Engl J Med"},{"issue":"6","key":"1506_CR216","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/wnl.59.6.880","volume":"59","author":"PP Zandi","year":"2002","unstructured":"Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002;59(6):880\u20136. https:\/\/doi.org\/10.1212\/wnl.59.6.880.","journal-title":"Neurology"},{"key":"1506_CR217","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.673962","volume":"12","author":"T Khera","year":"2021","unstructured":"Khera T, Rangasamy V. Cognition and pain: a review. Front Psychol. 2021;12: 673962. https:\/\/doi.org\/10.3389\/fpsyg.2021.673962.","journal-title":"Front Psychol"},{"key":"1506_CR218","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejmech.2015.12.036","volume":"109","author":"M Migliore","year":"2016","unstructured":"Migliore M, Habrant D, Sasso O, Albani C, Bertozzi SM, Armirotti A, et al. Potent multitarget FAAH-COX inhibitors: design and structure-activity relationship studies. Eur J Med Chem. 2016;109:216\u201337. https:\/\/doi.org\/10.1016\/j.ejmech.2015.12.036.","journal-title":"Eur J Med Chem"},{"issue":"1\u20133","key":"1506_CR219","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejphar.2007.02.051","volume":"565","author":"S Holt","year":"2007","unstructured":"Holt S, Paylor B, Boldrup L, Alajakku K, Vandevoorde S, Sundstrom A, et al. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol. 2007;565(1\u20133):26\u201336. https:\/\/doi.org\/10.1016\/j.ejphar.2007.02.051.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1506_CR220","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.817","volume":"9","author":"S Drozdzal","year":"2021","unstructured":"Drozdzal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy-Mokrzynska A, et al. Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature. Pharmacol Res Perspect. 2021;9(4): e00817. https:\/\/doi.org\/10.1002\/prp2.817.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"1506_CR221","first-page":"945","volume":"34","author":"M Wong","year":"2005","unstructured":"Wong M, Chowienczyk P, Kirkham B. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Aust Fam Physician. 2005;34(11):945\u20138.","journal-title":"Aust Fam Physician"},{"key":"1506_CR222","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/B978-0-7020-4086-3.00038-2","volume":"119","author":"E Auriel","year":"2014","unstructured":"Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb Clin Neurol. 2014;119:577\u201384. https:\/\/doi.org\/10.1016\/B978-0-7020-4086-3.00038-2.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1506_CR223","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1345\/aph.1G451","volume":"40","author":"MA Gamulescu","year":"2006","unstructured":"Gamulescu MA, Schalke B, Schuierer G, Gabel VP. Optic neuritis with visual field defect\u2013possible Ibuprofen-related toxicity. Ann Pharmacother. 2006;40(3):571\u20133. https:\/\/doi.org\/10.1345\/aph.1G451.","journal-title":"Ann Pharmacother"},{"issue":"23","key":"1506_CR224","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2165\/00003495-200464230-00001","volume":"64","author":"G Onder","year":"2004","unstructured":"Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs. 2004;64(23):2619\u201327. https:\/\/doi.org\/10.2165\/00003495-200464230-00001.","journal-title":"Drugs"},{"issue":"5","key":"1506_CR225","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tins.2022.01.002","volume":"45","author":"D Li","year":"2022","unstructured":"Li D, Zhang J, Liu Q. Brain cell type-specific cholesterol metabolism and implications for learning and memory. Trends Neurosci. 2022;45(5):401\u201314. https:\/\/doi.org\/10.1016\/j.tins.2022.01.002.","journal-title":"Trends Neurosci"},{"issue":"9","key":"1506_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2020.183340","volume":"1862","author":"AO Sodero","year":"2020","unstructured":"Sodero AO, Barrantes FJ. Pleiotropic effects of statins on brain cells. Biochim Biophys Acta Biomembr. 2020;1862(9): 183340. https:\/\/doi.org\/10.1016\/j.bbamem.2020.183340.","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"1506_CR227","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040812","author":"Y Poitelon","year":"2020","unstructured":"Poitelon Y, Kopec AM, Belin S. Myelin fat facts: an overview of lipids and fatty acid metabolism. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9040812.","journal-title":"Cells"},{"issue":"8","key":"1506_CR228","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s11010-022-04621-y","volume":"478","author":"A Svec","year":"2023","unstructured":"Svec A, Adameova A. Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. Mol Cell Biochem. 2023;478(8):1661\u20137. https:\/\/doi.org\/10.1007\/s11010-022-04621-y.","journal-title":"Mol Cell Biochem"},{"issue":"Suppl","key":"1506_CR229","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1016\/j.mito.2007.03.002","volume":"7","author":"GP Littarru","year":"2007","unstructured":"Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7(Suppl):S168\u201374. https:\/\/doi.org\/10.1016\/j.mito.2007.03.002.","journal-title":"Mitochondrion"},{"key":"1506_CR230","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030718","author":"J Munch","year":"2023","unstructured":"Munch J, Prasuhn J, Laugwitz L, Fung CW, Chung BH, Bellusci M, et al. Neuroimaging in primary coenzyme-Q(10)-deficiency disorders. Antioxidants (Basel). 2023. https:\/\/doi.org\/10.3390\/antiox12030718.","journal-title":"Antioxidants (Basel)."},{"key":"1506_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.968039","volume":"14","author":"T Jamshidnejad-Tosaramandani","year":"2022","unstructured":"Jamshidnejad-Tosaramandani T, Kashanian S, Al-Sabri MH, Krocianova D, Clemensson LE, Gentreau M, et al. Statins and cognition: modifying factors and possible underlying mechanisms. Front Aging Neurosci. 2022;14: 968039. https:\/\/doi.org\/10.3389\/fnagi.2022.968039.","journal-title":"Front Aging Neurosci."},{"key":"1506_CR232","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-018-0110-3","volume":"7","author":"BG Schultz","year":"2018","unstructured":"Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl Neurodegener. 2018;7:5. https:\/\/doi.org\/10.1186\/s40035-018-0110-3.","journal-title":"Transl Neurodegener."},{"issue":"6","key":"1506_CR233","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1592\/phco.21.7.767.34577","volume":"21","author":"A Orsi","year":"2001","unstructured":"Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767\u20139. https:\/\/doi.org\/10.1592\/phco.21.7.767.34577.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"1506_CR234","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1592\/phco.23.15.1663.31953","volume":"23","author":"DS King","year":"2003","unstructured":"King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23(12):1663\u20137. https:\/\/doi.org\/10.1592\/phco.23.15.1663.31953.","journal-title":"Pharmacotherapy"},{"key":"1506_CR235","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13256-016-0877-8","volume":"10","author":"C Suraweera","year":"2016","unstructured":"Suraweera C, de Silva V, Hanwella R. Simvastatin-induced cognitive dysfunction: two case reports. J Med Case Rep. 2016;10:83. https:\/\/doi.org\/10.1186\/s13256-016-0877-8.","journal-title":"J Med Case Rep"},{"issue":"7","key":"1506_CR236","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","volume":"23","author":"LR Wagstaff","year":"2003","unstructured":"Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871\u201380. https:\/\/doi.org\/10.1592\/phco.23.7.871.32720.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1506_CR237","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"MA Evans","year":"2009","unstructured":"Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800\u201311. https:\/\/doi.org\/10.1592\/phco.29.7.800.","journal-title":"Pharmacotherapy"},{"key":"1506_CR238","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs [2-28-2012] . Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs. Accessed Dec 3, 2024;"},{"issue":"1","key":"1506_CR239","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13041-021-00758-x","volume":"14","author":"Y Guo","year":"2021","unstructured":"Guo Y, Zou G, Qi K, Jin J, Yao L, Pan Y, et al. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. Mol Brain. 2021;14(1):41. https:\/\/doi.org\/10.1186\/s13041-021-00758-x.","journal-title":"Mol Brain"},{"key":"1506_CR240","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1606711","author":"B Tan","year":"2019","unstructured":"Tan B, Rosenfeldt F, Ou R, Stough C. Evidence and mechanisms for statin-induced cognitive decline. Expert Rev Clin Pharmacol. 2019. https:\/\/doi.org\/10.1080\/17512433.2019.1606711.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"11","key":"1506_CR241","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","volume":"117","author":"MF Muldoon","year":"2004","unstructured":"Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11):823\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2004.07.041.","journal-title":"Am J Med"},{"issue":"4","key":"1506_CR242","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1345\/aph.1Q620","volume":"46","author":"CH Rojas-Fernandez","year":"2012","unstructured":"Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549\u201357. https:\/\/doi.org\/10.1345\/aph.1Q620.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"1506_CR243","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","volume":"88","author":"KJ Swiger","year":"2013","unstructured":"Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213\u201321. https:\/\/doi.org\/10.1016\/j.mayocp.2013.07.013.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1506_CR244","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/CRD.0000000000000359","volume":"29","author":"B Chadha","year":"2021","unstructured":"Chadha B, Frishman WH. Review of the protective effects of statins on cognition. Cardiol Rev. 2021;29(6):328\u201335. https:\/\/doi.org\/10.1097\/CRD.0000000000000359.","journal-title":"Cardiol Rev"},{"issue":"3","key":"1506_CR245","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","volume":"30","author":"BR Ott","year":"2015","unstructured":"Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348\u201358. https:\/\/doi.org\/10.1007\/s11606-014-3115-3.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"1506_CR246","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804\u201314. https:\/\/doi.org\/10.1093\/eurjpc\/zwab208.","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"1506_CR247","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jacc.2024.01.030","volume":"83","author":"F Rea","year":"2024","unstructured":"Rea F, Corrao G, Mancia G. Risk of dementia during antihypertensive drug therapy in the elderly. J Am Coll Cardiol. 2024;83(13):1194\u2013203. https:\/\/doi.org\/10.1016\/j.jacc.2024.01.030.","journal-title":"J Am Coll Cardiol"},{"key":"1506_CR248","doi-asserted-by":"publisher","first-page":"4368474","DOI":"10.1155\/2017\/4368474","volume":"2017","author":"G Xu","year":"2017","unstructured":"Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, et al. Association between antihypertensive drug use and the incidence of cognitive decline and dementia: a meta-analysis of prospective cohort studies. Biomed Res Int. 2017;2017:4368474. https:\/\/doi.org\/10.1155\/2017\/4368474.","journal-title":"Biomed Res Int"},{"issue":"11","key":"1506_CR249","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003821","volume":"18","author":"C Bhanu","year":"2021","unstructured":"Bhanu C, Nimmons D, Petersen I, Orlu M, Davis D, Hussain H, et al. Drug-induced orthostatic hypotension: a systematic review and meta-analysis of randomised controlled trials. PLoS Med. 2021;18(11): e1003821. https:\/\/doi.org\/10.1371\/journal.pmed.1003821.","journal-title":"PLoS Med"},{"issue":"2","key":"1506_CR250","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10286-011-0119-5","volume":"21","author":"R Freeman","year":"2011","unstructured":"Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69\u201372. https:\/\/doi.org\/10.1007\/s10286-011-0119-5.","journal-title":"Clin Auton Res"},{"issue":"Suppl 1","key":"1506_CR251","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/pme.12915","volume":"16","author":"A Chen","year":"2015","unstructured":"Chen A, Ashburn MA. Cardiac effects of opioid therapy. Pain Med. 2015;16(Suppl 1):S27-31. https:\/\/doi.org\/10.1111\/pme.12915.","journal-title":"Pain Med"},{"issue":"3","key":"1506_CR252","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2165\/00002512-199506030-00005","volume":"6","author":"TF Mets","year":"1995","unstructured":"Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging. 1995;6(3):219\u201328. https:\/\/doi.org\/10.2165\/00002512-199506030-00005.","journal-title":"Drugs Aging"},{"issue":"10","key":"1506_CR253","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40266-020-00796-5","volume":"37","author":"G Rivasi","year":"2020","unstructured":"Rivasi G, Rafanelli M, Mossello E, Brignole M, Ungar A. Drug-related orthostatic hypotension: beyond anti-hypertensive medications. Drugs Aging. 2020;37(10):725\u201338. https:\/\/doi.org\/10.1007\/s40266-020-00796-5.","journal-title":"Drugs Aging"},{"key":"1506_CR254","doi-asserted-by":"publisher","first-page":"204800402095462","DOI":"10.1177\/2048004020954628","volume":"9","author":"A Buckley","year":"2020","unstructured":"Buckley A, Carey D, Meaney JM, Kenny R, Harbison J. Is there an association between orthostatic hypotension and cerebral white matter hyperintensities in older people? The Irish longitudinal study on ageing. JRSM Cardiovasc Dis. 2020;9:2048004020954628. https:\/\/doi.org\/10.1177\/2048004020954628.","journal-title":"JRSM Cardiovasc Dis"},{"issue":"1","key":"1506_CR255","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5853\/jos.2019.01844","volume":"22","author":"JS Kim","year":"2020","unstructured":"Kim JS, Lee S, Suh SW, Bae JB, Han JH, Byun S, et al. Association of low blood pressure with white matter hyperintensities in elderly individuals with controlled hypertension. J Stroke. 2020;22(1):99\u2013107. https:\/\/doi.org\/10.5853\/jos.2019.01844.","journal-title":"J Stroke"},{"issue":"4","key":"1506_CR256","first-page":"2410","volume":"14","author":"D Wei","year":"2022","unstructured":"Wei D, Wang Y, Yang X, Jin L. Association of white mater lesions with orthostatic hypotension. Am J Transl Res. 2022;14(4):2410\u20138.","journal-title":"Am J Transl Res."},{"issue":"8","key":"1506_CR257","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/jch.12550","volume":"17","author":"JC Foster-Dingley","year":"2015","unstructured":"Foster-Dingley JC, Moonen JE, van den Berg-Huijsmans AA, de Craen AJ, de Ruijter W, van der Grond J, et al. Lower blood pressure and gray matter integrity loss in older persons. J Clin Hypertens (Greenwich). 2015;17(8):630\u20137. https:\/\/doi.org\/10.1111\/jch.12550.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1506_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123026","volume":"461","author":"NLP Starmans","year":"2024","unstructured":"Starmans NLP, Wolters FJ, Leeuwis AE, Bron EE, de Bresser J, Brunner-La Rocca HP, et al. Orthostatic hypotension, cognition and structural brain imaging in hemodynamically impaired patients. J Neurol Sci. 2024;461: 123026. https:\/\/doi.org\/10.1016\/j.jns.2024.123026.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1506_CR259","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1161\/HYPERTENSIONAHA.122.18557","volume":"79","author":"I Raber","year":"2022","unstructured":"Raber I, Belanger MJ, Farahmand R, Aggarwal R, Chiu N, Al Rifai M, et al. Orthostatic hypotension in hypertensive adults: harry goldblatt award for early career investigators 2021. Hypertension. 2022;79(11):2388\u201396. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.18557.","journal-title":"Hypertension"},{"key":"1506_CR260","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.exger.2019.02.017","volume":"120","author":"R Iseli","year":"2019","unstructured":"Iseli R, Nguyen VTV, Sharmin S, Reijnierse EM, Lim WK, Maier AB. Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis. Exp Gerontol. 2019;120:40\u20139. https:\/\/doi.org\/10.1016\/j.exger.2019.02.017.","journal-title":"Exp Gerontol"},{"issue":"6","key":"1506_CR261","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40266-022-00951-0","volume":"39","author":"G Bahat","year":"2022","unstructured":"Bahat G, Ilhan B, Tufan A, Kilic C, Karan MA, Petrovic M. Hypotension under antihypertensive treatment and incident hospitalizations of nursing home residents. Drugs Aging. 2022;39(6):477\u201384. https:\/\/doi.org\/10.1007\/s40266-022-00951-0.","journal-title":"Drugs Aging"},{"issue":"1","key":"1506_CR262","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/WNL.0000000000003452","volume":"88","author":"J Centi","year":"2017","unstructured":"Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017;88(1):17\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000003452.","journal-title":"Neurology"},{"issue":"10","key":"1506_CR263","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1212\/WNL.0000000000201659","volume":"100","author":"I Ruiz Barrio","year":"2023","unstructured":"Ruiz Barrio I, Miki Y, Jaunmuktane ZT, Warner T, De Pablo-Fernandez E. Association between orthostatic hypotension and dementia in patients with parkinson disease and multiple system atrophy. Neurology. 2023;100(10):e998\u20131008. https:\/\/doi.org\/10.1212\/WNL.0000000000201659.","journal-title":"Neurology"},{"issue":"12","key":"1506_CR264","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/annonc\/mdz410","volume":"30","author":"M Lange","year":"2019","unstructured":"Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdz410.","journal-title":"Ann Oncol"},{"issue":"21","key":"1506_CR265","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2017.76.4696","volume":"36","author":"KR Krull","year":"2018","unstructured":"Krull KR, Hardy KK, Kahalley LS, Schuitema I, Kesler SR. Neurocognitive outcomes and interventions in long-term survivors of childhood cancer. J Clin Oncol. 2018;36(21):2181\u20139. https:\/\/doi.org\/10.1200\/JCO.2017.76.4696.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1506_CR266","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3109\/09540261.2013.864260","volume":"26","author":"MC Janelsins","year":"2014","unstructured":"Janelsins MC, Kesler SR, Ahles TA, Morrow GR. Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry. 2014;26(1):102\u201313. https:\/\/doi.org\/10.3109\/09540261.2013.864260.","journal-title":"Int Rev Psychiatry"},{"issue":"4","key":"1506_CR267","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrurol.2011.29","volume":"8","author":"R Zachariae","year":"2011","unstructured":"Zachariae R, Mehlsen MY. Is chemotherapy associated with cognitive impairment? Nat Rev Urol. 2011;8(4):182\u20133. https:\/\/doi.org\/10.1038\/nrurol.2011.29.","journal-title":"Nat Rev Urol"},{"issue":"6","key":"1506_CR268","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.mcna.2017.06.006","volume":"101","author":"TD Vannorsdall","year":"2017","unstructured":"Vannorsdall TD. Cognitive changes related to cancer therapy. Med Clin North Am. 2017;101(6):1115\u201334. https:\/\/doi.org\/10.1016\/j.mcna.2017.06.006.","journal-title":"Med Clin North Am"},{"issue":"5","key":"1506_CR269","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1037\/neu0000064","volume":"28","author":"OC Lindner","year":"2014","unstructured":"Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28(5):726\u201340. https:\/\/doi.org\/10.1037\/neu0000064.","journal-title":"Neuropsychology"},{"key":"1506_CR270","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071726","volume":"380","author":"B Fleming","year":"2023","unstructured":"Fleming B, Edison P, Kenny L. Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management. BMJ. 2023;380: e071726. https:\/\/doi.org\/10.1136\/bmj-2022-071726.","journal-title":"BMJ"},{"issue":"2","key":"1506_CR271","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrclinonc.2014.147","volume":"12","author":"PG Lawlor","year":"2015","unstructured":"Lawlor PG, Bush SH. Delirium in patients with cancer: assessment, impact, mechanisms and management. Nat Rev Clin Oncol. 2015;12(2):77\u201392. https:\/\/doi.org\/10.1038\/nrclinonc.2014.147.","journal-title":"Nat Rev Clin Oncol"},{"key":"1506_CR272","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/610813","volume":"2015","author":"R Fischer","year":"2015","unstructured":"Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev. 2015;2015: 610813. https:\/\/doi.org\/10.1155\/2015\/610813.","journal-title":"Oxid Med Cell Longev"},{"key":"1506_CR273","doi-asserted-by":"publisher","unstructured":"Brandl S, Reindl M. Blood-Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models. Int J Mol Sci. 2023;24(16). https:\/\/doi.org\/10.3390\/ijms241612699","DOI":"10.3390\/ijms241612699"},{"issue":"11","key":"1506_CR274","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1111\/ejn.12007","volume":"36","author":"MS Nokia","year":"2012","unstructured":"Nokia MS, Anderson ML, Shors TJ. Chemotherapy disrupts learning, neurogenesis and theta activity in the adult brain. Eur J Neurosci. 2012;36(11):3521\u201330. https:\/\/doi.org\/10.1111\/ejn.12007.","journal-title":"Eur J Neurosci"},{"issue":"1\u20132","key":"1506_CR275","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cytogfr.2012.01.001","volume":"23","author":"C Fritz-French","year":"2012","unstructured":"Fritz-French C, Tyor W. Interferon-alpha (IFNalpha) neurotoxicity. Cytokine Growth Factor Rev. 2012;23(1\u20132):7\u201314. https:\/\/doi.org\/10.1016\/j.cytogfr.2012.01.001.","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01506-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01506-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:02:58Z","timestamp":1749319378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01506-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":275,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01506-5","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"4 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Lund University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Arne Reimers: conceptualisation, methodology, investigation, writing\u2014original draft, writing\u2014review and editing. Per Odin: writing\u2014review and editing. Hanna Ljung: conceptualisation, methodology, writing\u2014review and editing, supervision. All authors have read and agreed to the submitted version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}